Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 3/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16754303 | 0.88 | GSK3B (0.38) | FGFR4ABL1WNT3AIRAK4JAK3 | |
| SCHEMBL16754282 | 0.87 | KARS1 (0.40) | ABL1WNT3AMAPK1MTOR | |
| SCHEMBL17778323 | 0.87 | KARS1 (0.40) | ABL1WNT3AMAPK1MTOR | |
| SCHEMBL16754400 | 0.87 | PRKD1 (0.37) | ABL1WNT3AIRAK4USP30MAPK1 | |
| SCHEMBL17618509 | 0.86 | WNT3A (0.41) | ABL1WNT3ADYRK1A | |
| SCHEMBL17778914 | 0.86 | DYRK1A (0.43) | ABL1IRAK4DYRK1A | |
| SCHEMBL16754671 | 0.86 | HRH3 (0.38) | ABL1WNT3AUSP30MTOR | |
| SCHEMBL17778803 | 0.86 | DYRK1A (0.42) | ABL1WNT3AIRAK4USP30MAPK1 | |
| SCHEMBL19689811 | 0.86 | DYRK1A (0.42) | ABL1WNT3AIRAK4USP30MAPK1 | |
| SCHEMBL19699129 | 0.86 | WNT3A (0.41) | FGFR4ABL1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | FGFR4 1754/4885ABL1 4089/4885WNT3A 4291/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | FGFR4 1754/4885ABL1 4089/4885WNT3A 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.